APA

Chesney J., Awasthi S., Curti B., Hutchins L., Linette G., Triozzi P., Tan M. C. B., Brown R. E., Nemunaitis J., Whitman E., Windham C., Lutzky J., Downey G. F., Batty N. & Amatruda T. (20180817). Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. : Melanoma research.

Chicago

Chesney Jason, Awasthi Sanjay, Curti Brendan, Hutchins Laura, Linette Gerald, Triozzi Pierre, Tan Marcus C B, Brown Russell E, Nemunaitis John, Whitman Eric, Windham Christopher, Lutzky Jose, Downey Gerald F, Batty Nicolas and Amatruda Thomas. 20180817. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. : Melanoma research.

Harvard

Chesney J., Awasthi S., Curti B., Hutchins L., Linette G., Triozzi P., Tan M. C. B., Brown R. E., Nemunaitis J., Whitman E., Windham C., Lutzky J., Downey G. F., Batty N. and Amatruda T. (20180817). Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. : Melanoma research.

MLA

Chesney Jason, Awasthi Sanjay, Curti Brendan, Hutchins Laura, Linette Gerald, Triozzi Pierre, Tan Marcus C B, Brown Russell E, Nemunaitis John, Whitman Eric, Windham Christopher, Lutzky Jose, Downey Gerald F, Batty Nicolas and Amatruda Thomas. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. : Melanoma research. 20180817.